TFS Capital’s Endocyte, Inc. Common Stock ECYT Stock Holding History

TFS Capital’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-20,974	Closed	-$65K	–	987
2016 Q3	$65K	Buy	+20,974	New	+$65.4K	0.02%	696
2016 Q1	–	Sell	-34,306	Closed	-$138K	–	1173
2015 Q4	$138K	Buy	34,306 +24,115	+237%	+$111K	0.01%	624
2015 Q3	$47K	Sell	10,191 -826	-7%	-$4.32K	﹤0.01%	847
2015 Q2	$57K	Sell	11,017 -36,705	-77%	-$220K	0.01%	850
2015 Q1	$299K	Sell	47,722 -2,681	-5%	-$15.5K	0.03%	685
2014 Q4	$317K	Buy	50,403 +33,960	+207%	+$207K	0.03%	714
2014 Q3	$100K	Buy	16,443 +1,851	+13%	+$12.6K	0.01%	970
2014 Q2	$96K	Buy	+14,592	New	+$164K	0.01%	1053
2013 Q3	–	Sell	-86,516	Closed	-$1.14M	–	1726
2013 Q2	$1.14M	Buy	+86,516	New	+$1.17M	0.05%	554

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's ECYT Position: Q4 2016 in Review

TFS Capital sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2016, closing a stake of 20,974 shares — an estimated $65K sold.

TFS Capital first reported a position in ECYT in Q2 2013 and held it in 9 quarters. The position peaked at $1.14M in Q2 2013. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

TFS Capital reported no remaining Endocyte, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
TFS Capital sold 20,974 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $65K.
TFS Capital first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
TFS Capital's Endocyte, Inc. Common Stock position peaked at $1.14M in Q2 2013.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.